These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 8137036)

  • 1. Side effects of HMG CoA reductase inhibitors.
    Ahmad S
    Heart Dis Stroke; 1993; 2(3):262-3. PubMed ID: 8137036
    [No Abstract]   [Full Text] [Related]  

  • 2. Lupuslike syndrome associated with simvastatin.
    Bannwarth B; Miremont G; Papapietro PM
    Arch Intern Med; 1992 May; 152(5):1093. PubMed ID: 1510761
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase].
    Martinez-García FA; Martín-Fernández J; Moltó JM; Villaverde R; Morales A; Fernández-Barreiro A
    Rev Neurol; 1997 Jun; 25(142):869-71. PubMed ID: 9244616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HMG-CoA reductase inhibitors and sexual dysfunction].
    Pía Iglesias G; Fernández Fernández FJ; Ameneiros Lago E; Sesma Sánchez P
    An Med Interna; 2001 Mar; 18(3):171. PubMed ID: 11594194
    [No Abstract]   [Full Text] [Related]  

  • 5. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin-induced lupus erythematosus.
    Ahmad S
    Arch Intern Med; 1991 Aug; 151(8):1667-8. PubMed ID: 1872674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
    Tobert JA
    Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
    Kotyla PJ; Sliwinska-Kotyla B; Kucharz EJ
    J Rheumatol; 2006 Nov; 33(11):2361-3; author reply 2363. PubMed ID: 17086617
    [No Abstract]   [Full Text] [Related]  

  • 9. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
    Landesman KA; Stozek M; Freeman NJ
    Conn Med; 1999 Aug; 63(8):455-7. PubMed ID: 10500341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premature coronary disease in systemic lupus.
    Noël B
    N Engl J Med; 2004 Apr; 350(15):1571-5; author reply 1571-5. PubMed ID: 15074009
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
    Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
    Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms.
    Lopez D; Chambers CM; Ness GC
    Arch Biochem Biophys; 1997 Jul; 343(1):118-22. PubMed ID: 9210653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of statins in lupus erythematosus.
    Noël B
    Arch Intern Med; 2004 Jan; 164(1):107-8. PubMed ID: 14718334
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase lower fecundity in the German cockroach: correlation between the effects on fecundity in vivo with the inhibition of enzymatic activity in embryo cells.
    Zapata R; Piulachs MD; Bellés X
    Pest Manag Sci; 2003 Oct; 59(10):1111-7. PubMed ID: 14561068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Rogers JD; Zhao J; Liu L; Amin RD; Gagliano KD; Porras AG; Blum RA; Wilson MF; Stepanavage M; Vega JM
    Clin Pharmacol Ther; 1999 Oct; 66(4):358-66. PubMed ID: 10546919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
    Drown DJ
    Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii.
    Hedl M; Rodwell VW
    Protein Sci; 2004 Jun; 13(6):1693-7. PubMed ID: 15152097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
    Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR
    Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitor-induced impotence.
    Halkin A; Lossos IS; Mevorach D
    Ann Pharmacother; 1996 Feb; 30(2):192. PubMed ID: 8835058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.